Aiolos Bio
AcquiredHome | GSK
San Francisco, United States · Founded 2023 · $245.0M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2023
- Business Model
- B2B
- Website
- aiolosbio.com
- Total Funding
- $245.0M
- Last Round
- $245.0M Series AOct 2023
- Rounds
- 1
- Acquisition Date
- Feb 2024
About
Aiolos Bio was a San Francisco Bay Area-based clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment landscape for respiratory and inflammatory diseases. Founded in 2023, the company launched with a $245 million Series A financing round co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments. Its lead asset, AIO-001, is a novel long-acting monoclonal antibody targeting TSLP designed to treat asthma with twice-yearly dosing. GSK acquired Aiolos Bio in February 2024 for up to $1.4 billion including $1 billion upfront.
Summary
Aiolos Bio is a biopharmaceuticals company based in San Francisco, United States, founded in 2023. It has raised $245.0M in total across 1 round, most recently a $245.0M Series A round in Oct 2023. Investors include GlaxoSmithKline, Atlas Venture and Bain Capital Life Sciences.
Tech & App Stack
2 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.